Recent changes in the number of outstanding shares of and votes in QuickCool AB (publ) has resulted in the dilution of Biovation Sciences Ltd's shareholding to 15.63 percent from 29.95 percent of the total number of outstanding shares of and votes in QuickCool AB (publ). No change in the number of shares held by Biovation Sciences Ltd has occurred. Biovation Sciences Ltd held and continues to hold 1.590.000 shares and votes in QuickCool AB (publ). The total number of registered QuickCool shares at EuroClear is 10 172 315 shares.
 

For more information, please contact:

Fredrik Radencrantz, CEO

Phone: 046-286 38 40

E-mail: fredrik.radencrantz@quickcool.se

This information is such that QuickCool AB is required to make public in accordance with the EU's market abuse regulation (MAR). The information was made publicly available by the Company's contact person on 17 March 2020.

Quickcool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool's solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool's Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se